Ionis Pharmaceuticals (IONS) Resumen de Acciones
Ionis Pharmaceuticals, Inc, empresa de biotecnología en fase comercial, suministra medicamentos dirigidos al ARN en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 6/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en IONS a partir de nuestros controles de riesgos.
IONS Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Ionis Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$81.80 |
| Máximo en las últimas 52 semanas | US$86.74 |
| Mínimo de 52 semanas | US$40.03 |
| Beta | 0.37 |
| Cambio en 1 mes | 9.83% |
| Variación en 3 meses | 10.05% |
| Cambio de 1 año | 90.23% |
| Variación en 3 años | 95.79% |
| Variación en 5 años | 110.45% |
| Variación desde la OPV | 718.00% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 25
IONS: FDA Approvals And 2026 Readouts Will Test Balanced Expectations
The analyst price target for Ionis Pharmaceuticals has been raised from $62.78 to $79.71, with analysts citing the FDA approval of Tryngolza and updated assumptions for revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Ionis Pharmaceuticals centers on the FDA approval of Tryngolza and how this new product feeds into long term revenue, margin, and P/E assumptions.Artículo de análisis • Jun 22
Ionis Pharmaceuticals (IONS) Stock Could Be 26.6% Undervalued After New Olezarsen Data
Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on liver fat and a favorable safety profile in an ongoing extension study. See our latest analysis for Ionis Pharmaceuticals. Ionis Pharmaceuticals’ share price is US$74.12, with short term moves roughly flat as the 7 day share price return of 1.15% and 30 day share price return, down 1.91%, contrast with a much stronger 1 year total...Recent updates
Actualización de narrativa • Jun 25
IONS: FDA Approvals And 2026 Readouts Will Test Balanced Expectations
The analyst price target for Ionis Pharmaceuticals has been raised from $62.78 to $79.71, with analysts citing the FDA approval of Tryngolza and updated assumptions for revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Ionis Pharmaceuticals centers on the FDA approval of Tryngolza and how this new product feeds into long term revenue, margin, and P/E assumptions.Artículo de análisis • Jun 22
Ionis Pharmaceuticals (IONS) Stock Could Be 26.6% Undervalued After New Olezarsen Data
Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on liver fat and a favorable safety profile in an ongoing extension study. See our latest analysis for Ionis Pharmaceuticals. Ionis Pharmaceuticals’ share price is US$74.12, with short term moves roughly flat as the 7 day share price return of 1.15% and 30 day share price return, down 1.91%, contrast with a much stronger 1 year total...
Actualización de narrativa • Jun 11
IONS: Priority Review In Severe Triglycerides Will Drive 2026 Risk Reward Repricing
Analysts have lifted their average price target on Ionis Pharmaceuticals toward $115, reflecting renewed focus on the $3.5b-plus Tryngloza opportunity in severe hypertriglyceridemia and upcoming partnered Phase 3 readouts in 2026, while leaving the modeled fair value at about $100.92 as the discount rate and margin assumptions are fine tuned. Analyst Commentary Street research around Ionis Pharmaceuticals has centered on how much value to ascribe to Tryngloza and the broader pipeline, with recent work fine tuning price targets and risk assumptions rather than radically changing the fundamental narrative.Actualización de narrativa • May 28
IONS: Priority Review In Severe Triglycerides Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has moved from $96.73 to $100.92 as analysts factor in higher assumed revenue growth, a stronger profit margin profile, and a lower future P/E multiple, supported by a wave of higher price targets and fresh Buy initiations that highlight the potential of Tryngloza and upcoming partnered Phase 3 readouts. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has been active, with multiple firms adjusting price targets and launching new coverage.Artículo de análisis • May 11
Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues
Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...
Actualización de narrativa • May 02
IONS: Priority FDA Reviews In 2026 Will Support Stronger Earnings Power
Analysts have nudged the Ionis Pharmaceuticals fair value estimate higher to $130 from $120, citing a series of price target increases across the Street and updated assumptions around growth, profitability, and future P/E levels. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has leaned constructive, with a cluster of bullish analysts lifting price targets and reinforcing a positive view on execution and long term growth potential, even as one firm trimmed its target.Artículo de análisis • May 01
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) just released its first-quarter report and things are looking bullish. The...Actualización de narrativa • Apr 18
IONS: Priority Review For Severe Triglycerides Will Reframe 2026 Risk Reward Profile
Analysts have raised their fair value estimate for Ionis Pharmaceuticals by about $3 to $96.73, citing updated assumptions for higher revenue growth, a wider profit margin, and a lower future P/E multiple, along with a series of recent price target increases and positive ratings resets from major firms. Analyst Commentary Recent research updates on Ionis Pharmaceuticals have leaned constructive, with several firms lifting price targets and reiterating positive ratings following the latest quarterly results and pipeline updates.Actualización de narrativa • Apr 04
IONS: Priority FDA Reviews In 2026 Will Support Stronger Profitability Profile
Analysts have lifted the Ionis Pharmaceuticals fair value estimate by $3.24 to $120.00, as they factor in updated assumptions around revenue growth, profit margins, and future P/E multiples following recent price target increases across the Street. Analyst Commentary Bullish analysts have been lifting Ionis Pharmaceuticals price targets across several research updates, which feeds directly into the higher fair value estimate.Actualización de narrativa • Mar 20
IONS: Priority Review For Severe Triglycerides Will Shape 2026 Outlook
Ionis Pharmaceuticals' updated analyst price target moves higher to $93.90 from $90.67. Analysts point to recent target hikes, Q4 results commentary and upcoming 2026 catalysts as key supports for this shift.Seeking Alpha • Mar 20
Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative
Summary Ionis Pharmaceuticals (IONS) projects $2B+ peak revenue for Olezarsen, but I believe this is highly conservative given the U.S. addressable market. Olezarsen demonstrated a 72% reduction in triglycerides and 85% reduction in acute pancreatitis events, with no comparable competition in efficacy. Current guidance assumes reaching only 10% of the 1M high-risk U.S. sHTG patients, with pricing likely near $20,000 per patient annually. U.S.-only projections, limited initial rollout, and a robust pipeline suggest significant upside potential beyond current market expectations. Read the full article on Seeking AlphaActualización de narrativa • Mar 06
IONS: 2026 Regulatory Event Risk Will Test Elevated Expectations
Ionis Pharmaceuticals' fair value estimate has been raised from $43.00 to about $62.78 as analysts factor in higher long term revenue growth assumptions, updated margin expectations, and recent price target increases following Q4 results, olezarsen progress, and a busy 2026 catalyst calendar. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a more constructive stance on the story overall, but there are still threads of caution that matter if you are thinking about risk, valuation, and execution over the next couple of years.Actualización de narrativa • Feb 19
IONS: Late-Stage RNA Programs Will Support Stronger Future Profitability Profile
Analysts have lifted their price target on Ionis Pharmaceuticals by $10, citing updated expectations around revenue growth, profit margins and a lower future P/E assumption, as reflected in recent research from firms covering the stock. Analyst Commentary Recent Street research points to a generally constructive tone on Ionis Pharmaceuticals, with bullish analysts highlighting both valuation and execution angles in their updated work.Actualización de narrativa • Feb 05
IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook
Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate. Analyst Commentary Bullish Takeaways Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.Actualización de narrativa • Jan 22
IONS: Upcoming SHTG Data And Launch Execution Will Support Bullish Thesis
Analysts have lifted their fair value estimate for Ionis Pharmaceuticals to about US$90.63 from roughly US$89.40, citing updated models that reflect recent Q3 performance, higher assumed revenue growth and profit margins, as well as a lower future P/E. This comes alongside Street price target increases to US$94 and US$99 following Tryngolza driven strength and expectations around upcoming SHTG data.Actualización de narrativa • Jan 08
IONS: Late-Stage Data And New Launches Will Shape Balanced Risk Profile
Analysts nudged their fair value estimate for Ionis Pharmaceuticals higher from about $85.95 to roughly $89.40. They pointed to updated models that reflect recent price target increases, added expectations for Tryngolza in FCS and severe hypertriglyceridemia, and revised long term margin and P/E assumptions.Actualización de narrativa • Dec 24
IONS: Late-Stage RNA Pipeline Will Drive Stronger Profitability Outlook
Analysts have raised their fair value estimate for Ionis Pharmaceuticals from approximately $96 to about $117 per share, citing strong Q3 outperformance led by Tryngolza, expanded peak sales assumptions for key lipid programs, and growing confidence in the late-stage pipeline and path to profitability. Analyst Commentary Bullish analysts are increasingly constructive on Ionis Pharmaceuticals following a series of positive catalysts, including strong Q3 performance from Tryngolza, encouraging late-stage data, and visible progress toward breakeven and long term profitability.Actualización de narrativa • Dec 10
IONS: Late-Stage Data And Multiple Launches Will Shape Balanced Long-Term Outlook
Analysts have modestly raised their fair value estimate for Ionis Pharmaceuticals to approximately $86 per share. This reflects higher peak sales assumptions for Tryngolza and other late stage programs, a slightly richer pricing outlook in severe hypertriglyceridemia, and growing confidence in the company reaching multi billion dollar revenue and profitability in the early 2030s.Actualización de narrativa • Nov 26
IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.Actualización de narrativa • Nov 05
IONS: Continued Clinical Success Will Drive Meaningful Upside After Recent Regulatory Wins
The consensus analyst price target for Ionis Pharmaceuticals has increased significantly, rising from approximately $77 to over $82. Analysts cite robust clinical trial results, new product milestones, and a strengthened commercial outlook as key drivers behind their upward revisions.Artículo de análisis • Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) defied analyst predictions to release its third-quarter results, which were...Actualización de narrativa • Oct 22
Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.Actualización de narrativa • Oct 08
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $69.48 to $73.03, as analysts cite strong Phase 3 results across multiple programs and expanded opportunities in ultra-rare indications, which support increased sales and profit expectations. Analyst Commentary Recent analyst updates on Ionis Pharmaceuticals reveal a nuanced outlook as the company benefits from significant clinical milestones and expanding commercial prospects, but also faces some areas of uncertainty.Actualización de narrativa • Sep 23
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Analysts increased their price targets for Ionis Pharmaceuticals following "groundbreaking" Phase 3 data for olezarsen, blockbuster expectations, and a major regulatory win for Dawnzera, resulting in a modest consensus target rise from $68.35 to $69.48. Analyst Commentary Bullish analysts significantly raised price targets after Phase 3 trial data for olezarsen/Tryngolza in severe hypertriglyceridemia showed "groundbreaking" or "highly statistically significant" triglyceride reductions and, notably, the first proven benefit in reducing acute pancreatitis.Artículo de análisis • Sep 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up
Despite an already strong run, Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) shares have been powering on, with a gain of...Actualización de narrativa • Aug 27
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ consensus price target edged up to $59.19 as analysts cited favorable FDA approval and label for Dawnzera in hereditary angioedema, strong initial launches, and growing pipeline confidence as key drivers, outweighing modest concerns on Wainua revenues. Analyst Commentary FDA approval of Dawnzera with a favorable, broad label (including both every four and eight week dosing) and absence of major safety warnings, positioning it competitively against Takhzyro and Andembry in hereditary angioedema.Artículo de análisis • Aug 01
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS)
Celebrations may be in order for Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) shareholders, with the analysts delivering...Artículo de análisis • Jul 30
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rentabilidad de los accionistas
| IONS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.8% | 4.1% | 1.6% |
| 1Y | 90.2% | 41.1% | 18.6% |
Rentabilidad vs. Industria: IONS superó a la industria US Biotechs, que obtuvo un rendimiento del 41.1% el año pasado.
Rentabilidad vs. Mercado: IONS superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| IONS volatility | |
|---|---|
| IONS Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: IONS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de IONS (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1989 | 1,402 | Brett Monia | www.ionis.com |
Ionis Pharmaceuticals, Inc, empresa de biotecnología en fase comercial, suministra medicamentos dirigidos al ARN en Estados Unidos. La empresa ofrece TRYNGOLZA, que reduce los niveles de triglicéridos en adultos con síndrome de quilomicronemia familiar (SFC) y pancreatitis aguda; DAWNZERA, profiláctico para prevenir ataques de angioedema hereditario en adultos; WAINUA, para el tratamiento de la polineuropatía de la amiloidosis hereditaria mediada por transtiretina (ATTRv-PN) en adultos; y SPINRAZA, para pacientes pediátricos y adultos con atrofia muscular espinal (AME). También ofrece QALSODY para el tratamiento de la esclerosis lateral amiotrófica (ELA); TEGSEDI para el tratamiento de la ATTRv-PN en adultos; y WAYLIVRA para el tratamiento de la SFC y la lipodistrofia parcial familiar.
Resumen de fundamentos de Ionis Pharmaceuticals, Inc.
| Estadísticas fundamentales de IONS | |
|---|---|
| Capitalización bursátil | US$13.52b |
| Beneficios(TTM) | -US$326.98m |
| Ingresos (TTM) | US$1.06b |
12.8x
Ratio precio-ventas (PS)-41.3x
Ratio precio-beneficio (PE)¿Está IONS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de IONS | |
|---|---|
| Ingresos | US$1.06b |
| Coste de los ingresos | US$942.46m |
| Beneficio bruto | US$115.73m |
| Otros gastos | US$442.71m |
| Beneficios | -US$326.98m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.98 |
| Margen bruto | 10.94% |
| Margen de beneficio neto | -30.90% |
| Ratio deuda/patrimonio | 478.3% |
¿Cómo se ha desempeñado IONS a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 04:29 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ionis Pharmaceuticals, Inc. está cubierta por 43 analistas. 23 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| James Birchenough | Barclays |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |